Concepedia

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Subhashis Sarkar, Sachin Kumar Singh Chauhan, J.M. Daly, Alessandro Natoni, Heather Fairfield, Robert B. Henderson, Emma Nolan, Dawn Swan, Jinsong Hu, Michaela R. Reagan,

Cancer Immunology Immunotherapy · 2020 · 15 citations · 38 references

DOIFull text

Open access

Concepts

References

38

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

Salima Hacein‐Bey‐Abina, Alexandrine Garrigue, Gary P. Wang et al. · Journal of Clinical Investigation · 2008 · 1.8K citations · Full text

, , +14

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

, , +17

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Wen‐Kai Weng, Ronald Levy · Journal of Clinical Oncology · 2003 · 1.3K citations

, , +13

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

, , +17

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Thierry Façon, Shaji Kumar, Torben Plesner et al. · New England Journal of Medicine · 2019 · 987 citations · Full text

, , +13